10-K: Alpha Teknova Reports Fiscal Year 2024 Results, Navigates Market Challenges

Alpha Teknova reports a slight revenue increase for fiscal year 2024 while managing operating losses and focusing on strategic growth areas.

Summary

• Alpha Teknova, a producer of critical reagents, reported a revenue increase of $1.1 million, or 2.9%, for the fiscal year 2024, reaching $37.7 million compared to $36.7 million in 2023.
• The company experienced an operating loss of $26.1 million in 2024, an improvement from the $35.6 million loss in 2023.
• Excluding non-recurring charges, the operating loss was $24.8 million in 2024 compared to $29.8 million in 2023.
• Lab Essentials revenue increased slightly by 0.3%, while Clinical Solutions revenue increased by 5.3%.
• The company achieved an annual customer retention rate of approximately 95% for customers purchasing more than $10,000 annually.
• Alpha Teknova is focusing on high-growth areas like cell and gene therapy, mRNA vaccines, synthetic biology, and molecular diagnostics.
• The company completed a private placement in July 2024, generating gross proceeds of approximately $15.4 million.
• A reduction in workforce was implemented in January 2024, expected to yield annual cost savings of $6.4 million.
• The company entered into a Second Amended and Restated Credit Agreement in March 2025, providing for loan commitments up to $28.245 million.
• Management believes there is no longer substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue increased and operating losses decreased, the company still faces challenges such as net losses and a decrease in gross profit percentage. The successful capital raise and cost-saving measures are positive signs, but the overall outlook is cautiously optimistic.

Positives

• Revenue increased by 2.9% in 2024, indicating growth in the business.
• Operating losses decreased, showing improved financial management.
• Clinical Solutions revenue increased, highlighting success in a key growth area.
• High customer retention rate suggests strong customer relationships and product satisfaction.
• The July 2024 private placement provided additional capital to support operations.
• Workforce reduction is expected to result in significant cost savings.
• The Second Amended and Restated Credit Agreement provides financial flexibility.
• Management believes there is no longer substantial doubt about the company's ability to continue as a going concern.

Negatives

• The company incurred a net loss of $26.7 million in 2024.
• Gross profit percentage decreased due to non-recurring and non-cash charges related to inventory.
• The company is dependent on customers spending on and demand for its products.
• The company faces intense competition from larger, well-capitalized companies.
• The company is subject to stringent and evolving data privacy and information security laws.

Risks

• The company may incur losses in the future and may never achieve or maintain profitability.
• Operating results may fluctuate significantly, making them difficult to predict.
• The company is dependent on customers spending on and demand for its products.
• The company faces intense competition from larger, well-capitalized companies.
• The company is subject to stringent and evolving data privacy and information security laws.
• The company's internal computer systems, or those of its suppliers, customers, or contractors, have been and may in the future be subject to cyberattacks or security breaches.
• The company may need to seek additional financing in the future, which it may not be able to secure on favorable terms, if at all.

Future Outlook

The company aims to increase the proportion of customers purchasing custom and GMP-grade products by building lasting relationships and embedding its products within customers' key workflows as their product development matures. The company is also focused on expanding its manufacturing capabilities and improving operational efficiency.

Management Comments

• Management believes that there is no longer substantial doubt about the company's ability to continue as a going concern.
• Management believes that the company has access to adequate supplies of water for its manufacturing operations and currently does not anticipate that future drought conditions will have a material impact on its operating results.

Industry Context

The company participates in multiple market segments, including cell and gene therapy, mRNA therapies, molecular diagnostics, and genomics. The company expects to benefit from favorable industry preferences for customized products, high quality, and short turnaround times.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document mentions competitors such as Thermo Fisher, Millipore (Merck KGaA), Cytiva (Danaher), and Hardy Diagnostics, but does not provide a detailed comparison of financial performance or market share.

Legal Proceedings

• In August 2023, a former Teknova employee filed a claim with the California Labor and Workforce Development Agency alleging various causes of action under California's labor, wage, and hour laws.
• On June 6, 2024, a mediation took place, in the course of which Teknova agreed to settle the plaintiff's claims for $0.4 million.

Related Party Transactions

• Telegraph Hill Partners Management Company LLC, Stephen Gunstream, and Matthew Lowell participated in the July 2024 private placement.
• Telegraph Hill Partners Management Company LLC, Stephen Gunstream, Matthew Lowell, Damon Terrill, and the Mackowski Family Trust participated in the September 2023 Offerings.

Stakeholder Impact

• Shareholders may be concerned about the company's net losses and decreased gross profit percentage.
• Employees may be affected by the workforce reduction implemented in January 2024.
• Customers may benefit from the company's focus on high-growth areas and improved operational efficiency.
• Creditors are impacted by the Second Amended and Restated Credit Agreement.

Next Steps

• The company aims to increase the proportion of customers purchasing custom and GMP-grade products.
• The company is focused on expanding its manufacturing capabilities and improving operational efficiency.
• The company will continue to monitor economic uncertainty and its impact on the business.

Key Dates